Skip to main content
. 2022 Apr 22;17(4):e0266707. doi: 10.1371/journal.pone.0266707

Fig 2. Overall survival (OS) and progression-free survival (PFS) rates in the patients who received no previous chemotherapy vs the patients who received GC chemotherapy.

Fig 2

The OS rates were 75.0% and 58.3% at 6 months and 75.0% and 35.0% at 1 year in patients who received no previous chemotherapy and those who received GC chemotherapy, respectively. The median OS was 20.6 months (95% confidence interval [CI] 8.03–33.23) and 6.3 months (95% CI 2.97–9.56), respectively. The PFS rates were 62.5% and 20.0% at 6 months and 33.3% and 20.0% at 1 year), respectively. The median PFS was 8.1 months (95% CI 0.00–17.6) and 3.7 months (95% CI 1.69–5.71), respectively. There was no significant difference in the OS and PFS since treatment initiation between patients who underwent no chemotherapy and those who underwent GC (P = 0.625 and P = 0.334, respectively).